A Study of DT2216 in Relapsed/Refractory Malignancies

Conditions:   Solid Tumor;   Hematologic Malignancy Intervention:   Drug: DT2216 Sponsor:   Dialectic Therapeutics, Inc Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials